Article
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Breast cancer research and treatment - 1 Aug 2020
Chamberlin Mary D, Wells Jason D, Shee Kevin, Bean Jennifer R, Marotti Jonathan D, Wells Wendy A, Trask Heidi W, Kolling Fred W, Bhatt Ananta, Kaufman Peter A, Schwartz Gary N, Gemery John M, McNulty Nancy J, Tsapakos Michael J, Barth Richard J, Arrick Bradley A, Gui Jiang, Miller Todd W
Abstract excerpt
PURPOSE: Circulating tumor DNA in plasma may present a minimally invasive opportunity to identify tumor-derived mutations to inform selection of targeted therapies for individual patients, particularly in cases of oligometastatic disease where biopsy of multiple tumors is impractical. To assess the utility of plasma DNA as a "liquid biopsy" for precision oncology, we tested whether sequencing of plasma DNA is a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.